JP7128195B2 - 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 - Google Patents

細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 Download PDF

Info

Publication number
JP7128195B2
JP7128195B2 JP2019546144A JP2019546144A JP7128195B2 JP 7128195 B2 JP7128195 B2 JP 7128195B2 JP 2019546144 A JP2019546144 A JP 2019546144A JP 2019546144 A JP2019546144 A JP 2019546144A JP 7128195 B2 JP7128195 B2 JP 7128195B2
Authority
JP
Japan
Prior art keywords
chimeric protein
ox40l
cells
cd40l
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019546144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020508329A (ja
JP2020508329A5 (enExample
Inventor
シュライバー，テイラー
フロム，ジョージ
シルヴァ，サレシュ デ
Original Assignee
シャタック ラボ，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャタック ラボ，インコーポレイテッド filed Critical シャタック ラボ，インコーポレイテッド
Publication of JP2020508329A publication Critical patent/JP2020508329A/ja
Publication of JP2020508329A5 publication Critical patent/JP2020508329A5/ja
Priority to JP2022130749A priority Critical patent/JP2022159510A/ja
Application granted granted Critical
Publication of JP7128195B2 publication Critical patent/JP7128195B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019546144A 2017-02-27 2018-02-27 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 Active JP7128195B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022130749A JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762464002P 2017-02-27 2017-02-27
US62/464,002 2017-02-27
PCT/US2018/020040 WO2018157165A1 (en) 2017-02-27 2018-02-27 Methods of making and using extracellular domain-based chimeric proteins

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022130749A Division JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Publications (3)

Publication Number Publication Date
JP2020508329A JP2020508329A (ja) 2020-03-19
JP2020508329A5 JP2020508329A5 (enExample) 2021-04-08
JP7128195B2 true JP7128195B2 (ja) 2022-08-30

Family

ID=63253416

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019546144A Active JP7128195B2 (ja) 2017-02-27 2018-02-27 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2019546149A Active JP7260477B2 (ja) 2017-02-27 2018-02-27 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2022130749A Pending JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2023062366A Active JP7620045B2 (ja) 2017-02-27 2023-04-06 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2025003769A Withdrawn JP2025061180A (ja) 2017-02-27 2025-01-09 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2019546149A Active JP7260477B2 (ja) 2017-02-27 2018-02-27 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2022130749A Pending JP2022159510A (ja) 2017-02-27 2022-08-18 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法
JP2023062366A Active JP7620045B2 (ja) 2017-02-27 2023-04-06 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
JP2025003769A Withdrawn JP2025061180A (ja) 2017-02-27 2025-01-09 Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質

Country Status (15)

Country Link
US (8) US11332509B2 (enExample)
EP (2) EP3585425A4 (enExample)
JP (5) JP7128195B2 (enExample)
KR (1) KR102745835B1 (enExample)
CN (3) CN118994414A (enExample)
AU (2) AU2018223821B2 (enExample)
BR (1) BR112019017298A2 (enExample)
CA (2) CA3054127A1 (enExample)
IL (2) IL268198B2 (enExample)
MX (1) MX2019009812A (enExample)
MY (1) MY207687A (enExample)
PH (1) PH12019501533A1 (enExample)
SG (1) SG11201906465YA (enExample)
WO (2) WO2018157162A1 (enExample)
ZA (1) ZA201905488B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022159510A (ja) * 2017-02-27 2022-10-17 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7511469B2 (ja) 2017-09-27 2024-07-05 イノザイム ファーマ， インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
CA3103975A1 (en) * 2018-06-21 2019-12-26 Shattuck Labs, Inc. Heterodimeric proteins and uses thereof
AU2019327493A1 (en) * 2018-08-29 2021-03-04 Shattuck Labs, Inc. Combination therapies comprising sirp alpha-based chimeric proteins
CA3109349A1 (en) * 2018-08-29 2020-03-05 Shattuck Labs, Inc. Combination therapies comprising tim-3-based chimeric proteins
CN112912384A (zh) * 2018-08-29 2021-06-04 沙塔克实验室有限公司 组合疗法
CA3110498A1 (en) * 2018-08-31 2020-03-05 Yale University Enpp1 polypeptides and methods of using same
SG11202102272UA (en) * 2018-09-05 2021-04-29 Univ Arizona State Oncolytic virus platform to treat hematological cancer
EP3906038A4 (en) 2018-11-21 2022-06-01 Mayo Foundation for Medical Education and Research ADENOVIRUS AND METHODS OF USE OF ADENOVIRUS
EP3930851A4 (en) * 2019-02-28 2023-03-29 Shattuck Labs, Inc. COMBINATION THERAPIES
AU2020266125B2 (en) * 2019-04-29 2023-04-13 Mayo Foundation For Medical Education And Research Multivalent PD-L1 binding compounds for treating cancer
CN112111437B (zh) * 2020-05-25 2023-09-05 江南大学 2’-岩藻糖基乳糖产量提高的重组枯草芽孢杆菌及其构建方法
US11820824B2 (en) * 2020-06-02 2023-11-21 Arcus Biosciences, Inc. Antibodies to TIGIT
CN115916348A (zh) 2020-06-18 2023-04-04 基因泰克公司 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CN111808800B (zh) * 2020-07-20 2022-08-26 中南大学湘雅二医院 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用
IL301454A (en) * 2020-09-17 2023-05-01 Shattuck Labs Inc Clinical dosing of SIRP1A chimeric protein
EP4237000A4 (en) * 2020-11-02 2024-09-18 Athae Bio, Inc. TWO-DOMAIN MULTIMERIC FUSION PROTEINS
WO2022120191A1 (en) * 2020-12-03 2022-06-09 Shattuck Labs, Inc. Methods of treating cancer using tigit-and light-based chimeric proteins
CN116897202A (zh) * 2021-02-24 2023-10-17 科济生物医药（上海）有限公司 Tigit工程化细胞及其组合物
CN115260312B (zh) * 2021-04-30 2025-02-14 保诺科技（北京）有限公司 结合ox40的抗体或抗原结合片段
TW202320848A (zh) 2021-07-28 2023-06-01 美商建南德克公司 治療癌症之方法及組成物
WO2023056403A1 (en) 2021-09-30 2023-04-06 Genentech, Inc. Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists
CN115960247A (zh) * 2021-10-13 2023-04-14 苏州科锐迈德生物医药科技有限公司 基于t7rna聚合酶的融合多肽及其制备方法、用途
JP2024543025A (ja) * 2021-11-01 2024-11-19 シャタック ラボ，インコーポレイテッド 皮膚炎症治療のためのキメラタンパク質
CN114209815B (zh) * 2021-11-22 2024-04-26 山东大学 一种药物组合物及其制备方法和应用
WO2023105281A1 (en) * 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
CN115490771B (zh) * 2021-12-24 2026-04-28 合肥天港免疫药物有限公司 重组抗体及其应用
CN114196691B (zh) * 2021-12-28 2023-08-11 重庆澳龙生物制品有限公司 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用
IL317449A (en) 2022-06-07 2025-02-01 Genentech Inc Method for determining the efficacy of a lung cancer treatment comprising an anti-PD-L1 antagonist and an anti-TIGIT antibody-antagonist
CN117624375A (zh) * 2022-08-30 2024-03-01 北京卡替医疗技术有限公司 增强受体、表达增强受体的免疫细胞及其用途
CN116350748A (zh) * 2022-11-01 2023-06-30 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
CN116041542B (zh) * 2022-12-06 2026-02-17 上海恩凯细胞技术有限公司 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用
CN116037072B (zh) * 2023-02-24 2025-01-03 宁夏医科大学 一种血清抗体亲和分离材料的制备方法与应用
CN116925236B (zh) * 2023-05-12 2024-06-04 上海恩凯细胞技术有限公司 嵌合转换受体及其应用
AU2024314312A1 (en) * 2023-06-22 2025-10-30 Fbd Biologics Limited Multi-targeting protein complex and methods of use thereof
CN116982600B (zh) * 2023-09-14 2025-11-18 江苏集萃药康生物科技股份有限公司 一种cd69人源化小鼠模型的构建方法及其应用
CN119930791A (zh) * 2023-11-02 2025-05-06 重庆精准生物技术有限公司 特异性tigit肽段
WO2025140345A1 (zh) * 2023-12-29 2025-07-03 沈阳三生制药有限责任公司 一种tigit多肽及tigit/ctla4融合蛋白

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013000234A1 (en) 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd A novel recomnimant bifunctional fusion protein and its preparation and use
JP2013521311A (ja) 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
KR100283541B1 (ko) 1991-10-25 2001-03-02 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 신규 사이토킨
ATE360031T1 (de) 2000-01-03 2007-05-15 Tr Associates L L C Chimäre proteine und anwendungen
US20110041190A1 (en) 2002-10-31 2011-02-17 Tykocinski Mark L Novel chimeric proteins
US7696168B2 (en) * 2000-04-21 2010-04-13 Tufts Medical Center, Inc. G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
EP1685159B1 (en) 2003-10-03 2012-08-01 Brigham & Women's Hospital Tim-3 polypeptides
WO2005047337A1 (en) 2003-11-13 2005-05-26 Hanmi Pharmaceutical Co., Ltd. A pharmaceutical composition comprising an immunoglobulin fc region as a carrier
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
US20080131431A1 (en) 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
CN105837690A (zh) 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
EP2038303A2 (en) 2006-06-21 2009-03-25 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
US20100150931A1 (en) 2006-11-22 2010-06-17 Centre Hospitalier De L'universite De Montreal Novel receptor for cd40l and uses thereof
WO2008144029A1 (en) 2007-05-14 2008-11-27 The University Of Chicago Antibody-light fusion products for cancer therapeutics
PT2242512T (pt) 2008-01-15 2016-07-18 Univ Leland Stanford Junior Métodos para manipular a fagocitose mediada por cd47
WO2009114110A1 (en) 2008-03-08 2009-09-17 Immungene, Inc. Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
EP2460827A1 (en) 2008-06-30 2012-06-06 The Trustees Of The University Of Pennsylvania Fusion proteins comprising Fn14 and an inhibitory protein
KR20110044992A (ko) 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 ＴＧＦ-β 길항제 다중-표적 결합 단백질
EP3103875A1 (en) 2008-07-21 2016-12-14 Apogenix AG Tnfsf single chain molecules
US8183207B2 (en) 2008-11-26 2012-05-22 Five Prime Therapeutics, Inc. Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules
US8080246B2 (en) 2008-11-26 2011-12-20 Five Prime Therapeutics, Inc. Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules
CN102257001A (zh) * 2008-12-19 2011-11-23 诺瓦提斯公司 治疗自体免疫和炎性病症的可溶性多肽
US9221895B2 (en) 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
CN103153332A (zh) 2010-09-28 2013-06-12 卡尔医疗有限公司 用于治疗血液恶性肿瘤的组合物和方法
CN103261217B (zh) 2010-11-11 2017-04-26 港大科桥有限公司 可溶性 pd‑1变体、融合构建体及其用途
ES2608835T3 (es) 2011-04-13 2017-04-17 Bristol-Myers Squibb Company Proteínas de fusión Fc que comprenden nuevos enlazadores o disposiciones
US10179164B2 (en) 2011-05-25 2019-01-15 Cel-Sci Corporation Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions
PH12014500247A1 (en) 2011-07-29 2014-03-24 Univ Pennsylvania Switch costimulatory receptors
US9828432B2 (en) 2012-02-06 2017-11-28 Providence Health & Services—Oregon Cancer treatment and monitoring methods using OX40 agonists
WO2013164694A1 (en) 2012-04-30 2013-11-07 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
ES2924722T3 (es) 2012-05-18 2022-10-10 Aptevo Res & Development Llc Unión de inmunofusión de scFv biespecífico (BIf) a CD123 y CD3
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
HRP20192013T1 (hr) 2012-12-17 2020-02-07 Trillium Therapeutics Inc. Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
AU2013371826A1 (en) * 2013-01-01 2015-08-13 Kahr Medical Ltd. Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof
US20140242077A1 (en) 2013-01-23 2014-08-28 Abbvie, Inc. Methods and compositions for modulating an immune response
US10533054B2 (en) 2013-01-31 2020-01-14 Thomas Jefferson University Agonist fusion protein for CD40 and OX40 and methods of stimulating the immune system
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
WO2014121093A1 (en) 2013-01-31 2014-08-07 Thomas Jefferson University Fusion proteins that facilitate cancer cell destruction
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
US9657082B2 (en) 2013-01-31 2017-05-23 Thomas Jefferson University PD-L1 and PD-L2-based fusion proteins and uses thereof
BR112015020516A2 (pt) 2013-02-26 2017-10-10 Memorial Sloan Kettering Cancer Center composições e métodos para imunoterapia
PL2970512T3 (pl) 2013-03-12 2019-03-29 Biocon Limited Immunomodulujące białka fuzyjne i sposoby ich otrzymywania
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
US10196435B2 (en) 2013-11-18 2019-02-05 University Of Southern California OX40L fusion protein for the immunotherapy of tumors of veterinary animals
WO2015095423A2 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
US10927154B2 (en) 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
WO2015107331A2 (en) 2014-01-14 2015-07-23 Kymab Limited Anti-light antibodies
CA2936244A1 (en) 2014-01-21 2015-07-30 Medimmune, Llc Compositions and methods for modulating and redirecting immune responses
CN106459218B (zh) 2014-03-24 2021-03-02 宜明昂科生物医药技术（上海）有限公司 新的重组双功能融合蛋白、其制剂和用途
EP3148573A4 (en) 2014-05-29 2017-11-15 Medimmune, LLC Ox40l fusion proteins and uses thereof
EP3160497A4 (en) 2014-06-27 2018-01-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Conjugates for immunotherapy
WO2016023040A1 (en) 2014-08-08 2016-02-11 Alexo Therapeutics International Sirp-alpha variant constructs and uses thereof
SI3482766T1 (sl) 2014-08-11 2020-09-30 Delinia, Inc. Spremenjene variante IL-2, ki selektivno aktivirajo regulatorne T celice za zdravljenje avtoimunskih bolezni
DK3180363T3 (da) 2014-08-15 2019-11-04 Merck Patent Gmbh Sirp-alpha-immunoglobulin fusionsproteiner
EP3221360A1 (en) 2014-11-17 2017-09-27 F. Hoffmann-La Roche AG Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
WO2016112983A1 (en) * 2015-01-15 2016-07-21 Biontech Ag Cytokine fusion proteins
US11161907B2 (en) * 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
KR20170109582A (ko) 2015-02-06 2017-09-29 히트 바이오로직스, 인코퍼레이티드 벡터 공동 발현 백신 및 공동 자극 분자
WO2016166139A1 (en) 2015-04-14 2016-10-20 Eberhard Karls Universität Tübingen Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells
US9845345B2 (en) 2015-05-18 2017-12-19 Ab Initio Biotherapeutics, Inc. SIRP polypeptide compositions and methods of use
BR112018006578A2 (pt) 2015-10-01 2018-12-26 Heat Biologics, Inc. composições e métodos para juntar domínios extracelulares tipo i e tipo ii como proteínas quiméricas heterólogas
WO2018075960A1 (en) 2016-10-21 2018-04-26 Tioma Therapeutics, Inc. Therapeutic cd47 antibodies
CN118994414A (zh) * 2017-02-27 2024-11-22 沙塔克实验室有限公司 基于tigit和light的嵌合蛋白

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013521311A (ja) 2010-03-05 2013-06-10 ザ・ジョンズ・ホプキンス・ユニバーシティー 標的免疫調節抗体および融合タンパク質に基づく組成物および方法
WO2013000234A1 (en) 2011-06-28 2013-01-03 Huabo Biopharm Co., Ltd A novel recomnimant bifunctional fusion protein and its preparation and use
WO2017027422A1 (en) 2015-08-07 2017-02-16 Alexo Therapeutics Inc. Constructs having a sirp-alpha domain or variant thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Nature Medicine，2016年，22，1402-1410
Nature Reviews Clinical Oncology，2016年，13，143-158
Nature Reviews Drug Discovery，2015年，14，561-584

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022159510A (ja) * 2017-02-27 2022-10-17 シャタック ラボ，インコーポレイテッド 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法

Also Published As

Publication number Publication date
ZA201905488B (en) 2024-02-28
JP7620045B2 (ja) 2025-01-22
JP2020508329A (ja) 2020-03-19
AU2018223821B2 (en) 2022-05-19
JP2023076695A (ja) 2023-06-01
CN110381983B (zh) 2024-07-09
WO2018157165A1 (en) 2018-08-30
IL313003A (en) 2024-07-01
PH12019501533A1 (en) 2020-02-24
SG11201906465YA (en) 2019-08-27
US10927159B2 (en) 2021-02-23
AU2018223821A1 (en) 2019-07-11
RU2019125682A3 (enExample) 2021-12-03
EP3585418A1 (en) 2020-01-01
US20240190939A1 (en) 2024-06-13
US20200283496A1 (en) 2020-09-10
KR102745835B1 (ko) 2024-12-24
US12071465B2 (en) 2024-08-27
IL268198B1 (en) 2024-06-01
US10899817B2 (en) 2021-01-26
US20200399342A1 (en) 2020-12-24
JP2020508068A (ja) 2020-03-19
AU2022218575A1 (en) 2022-11-10
BR112019017298A2 (pt) 2020-04-14
MX2019009812A (es) 2019-10-14
US20190367579A1 (en) 2019-12-05
MY207687A (en) 2025-03-12
US20240368242A1 (en) 2024-11-07
US20220315637A1 (en) 2022-10-06
CN110234345A (zh) 2019-09-13
IL268198A (en) 2019-09-26
WO2018157162A1 (en) 2018-08-30
CA3054133A1 (en) 2018-03-30
CN110381983A (zh) 2019-10-25
CN118994414A (zh) 2024-11-22
EP3585425A4 (en) 2020-10-28
US20200222503A1 (en) 2020-07-16
EP3585425A1 (en) 2020-01-01
EP3585418A4 (en) 2020-11-25
JP7260477B2 (ja) 2023-04-18
RU2019125682A (ru) 2021-03-29
IL268198B2 (en) 2024-10-01
JP2025061180A (ja) 2025-04-10
US11332509B2 (en) 2022-05-17
KR20190122667A (ko) 2019-10-30
US20220227831A1 (en) 2022-07-21
JP2022159510A (ja) 2022-10-17
CA3054127A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
JP7620045B2 (ja) Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質
CN108350055B (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
JP2023071979A (ja) Ｖｓｉｇ８ベースのキメラタンパク質
RU2775490C2 (ru) Химерные белки на основе tigit и light
HK40101388A (en) Vsig8-based chimeric proteins
HK40091905A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法
HK40092182A (zh) 作为异源嵌合蛋白邻接i型和ii型胞外结构域的组合物和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191023

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20191129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20191202

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220629

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220719

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220818

R150 Certificate of patent or registration of utility model

Ref document number: 7128195

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150